The Basel Long COVID Cohort Study (BALCoS): protocol of a prospective cohort study

Competing Interest Statement

Conflict of Interest Statement GM received funding from the Stanley Thomas Johnson Stiftung & Gottfried und Julia–Bangerter–Rhyner–Stiftung under projects no. PC 28/17 and PC 05/18, from Health Promotion Switzerland under project no. 18.191/K50001, from the Swiss Heart Foundation under project no. FF21101, from the Research Foundation of the International Psychoanalytic University (IPU) Berlin under projects no. 5087 and 5217, from the Swiss National Science Foundation (SNSF) under project no. 100014_135328, from the German Federal Ministry of Education and Research under budget item 68606, from the Hasler Foundation under project No. 23004, from SERI under contract number 22.00094 in the context of a European Union (Horizon Europe) research consortium “Long COVID” (funding number: 101057553) and from Wings Health in the context of a proof–of–concept study. GM is a cofounder and shareholder of Therayou AG, active in digital and blended mental healthcare. GM receives royalties from publishing companies as author, including a book published by Springer, and an honorarium from Lundbeck for speaking at a symposium. Furthermore, GM is compensated for providing psychotherapy to patients, acting as a supervisor, serving as a self–experience facilitator (“Selbsterfahrungsleiter”), and for postgraduate training of psychotherapists, psychosomatic specialists, and supervisors. RaS received funding from Promotion Sante Suisse (Gesundheitsförderung Schweiz) under contract no. 18.191/ K50001, from the Health Department Basel–City, from SERI under contract number 22.00094 in the context of a European Union (Horizon Europe) research consortium “Long COVID” (funding number: 101057553), and from Wings Health in the context of a proof–of–concept study. RaS is co–editor of the German AWMF S3–Guidelines on Functional Complaints and contributed to the German guidelines on irritable bowel syndrome, and on Lyme Borreliosis. RaS is chairman of the Basel Institute for Psychosomatic Medicine (BIPM), and founder and managing director of the Psychosomatic and Psychosocial Services GmbH, that develops and implements psychosomatic and psychosocial training and continuing education programs. RaS is member of the Swiss Academy of Psychosomatic and Psychosocial Medicine (SAPPM) – where he is member of the Scientific Advisory Board, of the Société Médicale Suisse d′Hypnose (SMSH), of the Dt. Kollegium für Psychosomatische Medizin (DKPM), of the Dt. Gesellschaft für Psychosomatische Medizin und Ärztliche Psychotherapie (DGPM), and of the German Balint Society (DBG). RaS serves as spokesman of DKPM and DGPM for Consultation and Liaison Psychosomatics. He is a member of the board of trustees of the Foundation Psychosomatic and Social Medicine (Ascona Foundation). MM served as a consultant for AstraZeneca, Böhringer Ingelheim, Bayer and received unrestricted grants from Menarini, AstraZeneca, Bayer, Bristol–Myers Squibb Pfizer, Daiichi Sankyo, GlaxoSmithKline, IBSA, Lilly, MSD, Novo Nordisk, Sanofi–Aventis, and Viatris. ReS received funding from SERI under contract number 22.00094 in the context of a European Union (Horizon Europe) research consortium “Long COVID” (funding number: 101057553). AM received unrestricted grants from Menarini, AstraZeneca, Bayer, Bristol–Myers Squibb Pfizer, Daiichi Sankyo, GlaxoSmithKline, IBSA, Lilly, MSD, Novo Nordisk, Sanofi–Aventis, and Viatris.

Funding Statement

Funding Details BALCoS is primarily funded by the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract number 22.00094 in the context of the European Unions Horizon Europe research and innovation program under grant agreement No. 101057553.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study has been approved by the Department of Clinical Research at University Hospital Basel (ID: th22schaefert), the Ethics Commission of Northwest and Central Switzerland (ID: 2023-00359) and is registered at ClinicalTrial.gov (ID: NCT05781893).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes